BA
CARM

BlackRock Advisors’s Carisma Therapeutics CARM Stock Holding History

BlackRock Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,841
Closed -$273K – 3767
2015
Q2 		$273K Buy
4,841
+4,336
+859% +$612K ﹤0.01% 2604
2015
Q1 		$90K Buy
505
+409
+426% +$89.4K ﹤0.01% 3086
2014
Q4 		$23K Hold
96
– – ﹤0.01% 3472
2014
Q3 		$21K Hold
96
– – ﹤0.01% 3488
2014
Q2 		$25K Sell
96
-4,436
-98% -$1.1M ﹤0.01% 3392
2014
Q1 		$1.47M Buy
+4,532
New +$1.36M ﹤0.01% 1306

Other funds holding CARM

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's CARM Position: Q3 2015 in Review

BlackRock Advisors sold out of Carisma Therapeutics (CARM) in Q3 2015, closing a stake of 4,841 shares — an estimated $273K sold.

BlackRock Advisors first reported a position in CARM in Q1 2014 and held it in 6 quarters. The position peaked at $1.47M in Q1 2014. 30 funds tracked by Wall St. Rank hold CARM as of Q3 2015.

  • BlackRock Advisors reported no remaining Carisma Therapeutics position as of Q3 2015 after selling out during the quarter.
  • BlackRock Advisors sold 4,841 Carisma Therapeutics shares in Q3 2015, an estimated $273K.
  • BlackRock Advisors first reported a position in Carisma Therapeutics in Q1 2014 and held it in 6 quarters.
  • BlackRock Advisors's Carisma Therapeutics position peaked at $1.47M in Q1 2014.
  • 30 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2015.

Based on BlackRock Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.